Background:
The Supreme Court today held that the plaintiffs who challenged the FDA’s approval of mifepristone have no standing because they neither prescribe nor use the drug and therefore have no legal standing to bring the challenge forward.
The Court also stated that “[u]nder Article III of the Constitution, a plaintiff’s desire to make a drug less available for others does not establish standing to sue. Nor do the plaintiffs’ other standing theories suffice.”
This ruling means that the FDA’s approval remains in place and mifepristone will continue to be available for physicians to prescribe.
Statement:
“Today’s unanimous decision is a positive development for those advocating for reproductive rights and access to safe abortion methods, particularly given the extensive evidence supporting the drug’s safety and efficacy. We must continue to support policies and legal actions that protect and expand access to abortion, ensuring that all individuals have the right to make decisions about their own bodies without unnecessary restrictions,” said Attorney General Raúl Torrez.
…
